141 related articles for article (PubMed ID: 38378317)
61. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
[TBL] [Abstract][Full Text] [Related]
62. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
63. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
64. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
65. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
[TBL] [Abstract][Full Text] [Related]
66. NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms.
Croce S; Hostein I; McCluggage WG
Genes Chromosomes Cancer; 2021 Mar; 60(3):147-159. PubMed ID: 33099837
[TBL] [Abstract][Full Text] [Related]
67. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
Saleh K; Felefly T; Khalife N; Kourie HR
Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
[No Abstract] [Full Text] [Related]
68. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
69. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
70. Primary and Metastatic Melanoma With NTRK Fusions.
Lezcano C; Shoushtari AN; Ariyan C; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Aug; 42(8):1052-1058. PubMed ID: 29683819
[TBL] [Abstract][Full Text] [Related]
71. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
[TBL] [Abstract][Full Text] [Related]
72. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
73. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Morano F; Fucà G; Nikolinakos P; Drilon A; Hechtman JF; Christiansen J; Gowen K; Frampton GM; Gasparini P; Rossini D; Gigliotti C; Kim ST; Prisciandaro M; Hodgson J; Zaniboni A; Chiu VK; Milione M; Patel R; Miller V; Bardelli A; Novara L; Wang L; Pupa SM; Sozzi G; Ross J; Di Bartolomeo M; Bertotti A; Ali S; Trusolino L; Falcone A; de Braud F; Cremolini C
Ann Oncol; 2018 Jun; 29(6):1394-1401. PubMed ID: 29538669
[TBL] [Abstract][Full Text] [Related]
74. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
75. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB
Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662
[TBL] [Abstract][Full Text] [Related]
76. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?
Hang JF; Lee YC
Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120
[No Abstract] [Full Text] [Related]
77. RAF1 rearrangements are common in pancreatic acinar cell carcinomas.
Prall OWJ; Nastevski V; Xu H; McEvoy CRE; Vissers JHA; Byrne DJ; Takano E; Yerneni S; Ellis S; Green T; Mitchell CA; Murray WK; Scott CL; Grimmond SM; Hofmann O; Papenfuss A; Kee D; Fellowes A; Brown IS; Miller G; Kumarasinghe MP; Perren A; Nahm CB; Mittal A; Samra J; Ahadi M; Fox SB; Chou A; Gill AJ
Mod Pathol; 2020 Sep; 33(9):1811-1821. PubMed ID: 32358589
[TBL] [Abstract][Full Text] [Related]
78. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
79. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
80. Detection of
Solomon JP; Hechtman JF
Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
